nties, please see the Company's Annual Report on Form 10-K for 2006
and its most recent quarterly report on Form 10-Q.
CONTACT:
For Genta Incorporated
Tara Spiess
TS Communications Group, LLC
(908) 286-3980
info@genta.com
Genta Incorporated
Selected Condensed Consolidated Financial Data
(In thousands, except per share data)
(Unaudited)
Three Months Ended Six Months Ended
June 30 June 30
2007 2006 2007 2006
Product sales - net $105 $379 $199 $446
Cost of goods sold 26 22 48 38
Gross margin 79 357 151 408
Operating expenses:
Research and development 4,099 8,637 7,481 13,387
Selling, general and
administrative 4,735 6,716 8,787 12,173
Reduction in liability for
settlement of litigation (240) - (1,800) -
Total operating expenses 8,594 15,353 14,468 25,560
Other income 280 354 478 614
Net loss $(8,235) $(14,642) $(13,839) $(24,538)
Net loss per basic and diluted
share $(0.27) $(0.66) $(0.48) $(1.17)
Shares used in computing basic and
diluted net loss per share
(adjusted for 1-for-6 reverse
stock split on July 13, 2007) 30,621 22,278 28,604 20,995
Selected Condensed Consolidated Balance Sheet Data
'/>"/>
SOURCE Genta Incorporated
 Copyright©2007 PR Newswire. | |
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1.
Genta Announces Results of Phase 1 Study Using Genasense
Administered by Intermittent Subcutaneous Injection2.
Genta Incorporated to Present Multiple Abstracts at the Annual
Meeting of the American Society of Clinical Oncology3.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial4.
Sygnis Pharma AG announces date for presentation of clinical
results5.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis6.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis7.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial8.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine9.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis10.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone11.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease